Fig. 1From: SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney diseaseThe action sites of SGLT2 and RASS inhibitors and the potential synergistic mechanism of their combined therapy in T2DM. RASS renin–angiotensin-aldosterone system, T2DM type 2 diabetes mellitus, SGLT2 Sodium–glucose co-transporter 2Back to article page